Current Clinical Practice: Application of Resistance Reversal Agents in Hematologic Malignancies

References

• Dalton, W. S. (1997). Mechanisms of drug resistance in hematologic malignancy, Sem Hematol, 34(Suppl 5), 3–8.
   PubMedGoogle Scholar
• List, A. F. (1997). Non-P-glycoprotein drug export mechanisms of multidrug resistance, Sem Hematol, 34(Suppl 5), 20–24.
   PubMedGoogle Scholar
• Bhalla, K. N., Gerson, S. L., Grant, S. and Sullivan, D. M. (2000). Chapter 50: Pharmacology and molecular mechanism of action or resistance of antineoplastic agents: Current status and future potential. In Hematology: Basic principles and practice, edited by R. Hoffman, E. J. Benz, Jr., S. J. Shattil, B. Furie, H. J. Cohen, L. E. Silberstein and P. McGlave, pp. 885–920, Philadelphia. Churchill Livingstone.
   Google Scholar
• Juliano, R. L. and Ling, V. (1976). A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants, Biochemica et Biophysica Acta, 455, 152–162.
   PubMed Web of Science ®Google Scholar
• Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V. and Deeley, R. G. (1992). Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line, Science, 258, 1650–1654.
   PubMed Web of Science ®Google Scholar
• Lum, B. L., Fisher, G. A., Brophy, N. A., Yahanda, A. M., Adler, K. M., Kaubisch, S., Halsey, J. and Sikic, B. I. (1993). Clinical trials of modulation of multidrug resistance, Cancer, 72, 3502–3514.
   PubMed Web of Science ®Google Scholar
• Rosenberg, M. F., Callaghan, R., Ford, R. C. and Higgins, C. F. (1997). Structure of the multidrug resistance P-glycoprotein to 2.5 nm resolution determined by electron microscopy and image analysis, J Biol Client, 272, 10685–10694.
   Web of Science ®Google Scholar
• Abraham, E., Prat, A. G., Gerweck, L., Seneveratne, T., Arceci, R. J., Kramer, R., Guidotti, G. and Cantiello, H. F. (1993). The multidrug resistance (mdr1) gene product functions as an ATP channel, Proc Natl Acad Sci USA, 90, 312–316.
   PubMed Web of Science ®Google Scholar
• Higgins, C. F. (1995). P-glycoprotein and cell volume-activated chloride channels, J Bioenerg Biomembr, 27, 63–70.
   PubMed Web of Science ®Google Scholar
• Johnstone, R. W., Cretney, E. and Smyth, M. J. (1999). P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death, Blood, 93, 1075–1085.
   PubMed Web of Science ®Google Scholar
• Smyth, M. J., Krasovskis, E., Sutton, V. R. and Johnstone, R. W. (1998). The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis, Proc Natl Acad Sci USA, 95, 7024–7029.
   PubMed Web of Science ®Google Scholar
• Masci, A. M., Scala, S., Racioppi, L. and Zappacosta, S. (1995). Cell surface expression of major histocompatibility class I antigens is modulated by P-glycoprotein transporter, Hum Immunol, 42, 245–253.
   PubMed Web of Science ®Google Scholar
• Ueda, K., Cardarelli, C., Gottesman, M. M. and Pastan, I. (1987). Expression of a full length cDNA for the human “MDR1” gene confers resistance to colchicine, doxorubicin, and vinblastine, Proc Natl Acad Sci USA, 84, 3004–3008.
   PubMed Web of Science ®Google Scholar
• Mechetner, E. B. and Roninson, I. B. (1992). Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody, Proc Natl Acad Sci USA, 89, 5824–5828.
   PubMed Web of Science ®Google Scholar
• Holm, P. S., Scanlon, K. J. and Dietel, M. (1994). Reversion of multidrug resistance in the P-glycoprotein-positive cell line (EPP85–181RDB) by introduction of a hammerhead ribozyme, Br J Cancer, 70, 239–243.
   PubMed Web of Science ®Google Scholar
• Quattrone, A., Papucci, L., Morganti, M., Coronnello, M., Mini, E., Mazzei, T., Colonna, F. P., Garbesi, A. and Capaccioli, S. (1994). Inhibition of MDR1 gene expression by antimessenger oligonucleotides lowers multiple drug resistance, Oncol Res, 6, 311–320.
   PubMed Web of Science ®Google Scholar
• Nooter, K. and Sonneveld, P. (1994). Clinical relevance of P-glycoprotein expression in haematological malignancies, Leukemias Res, 18, 233–243.
   PubMed Web of Science ®Google Scholar
• Klimecki, W. T., Futscher, B. W., Grogan, T. M. and Dalton, W. S. (1994). P-glycoprotein expression and function in circulating blood cells from normal volunteers, Blood, 83, 2451–2458.
   PubMed Web of Science ®Google Scholar
• Gottesman, M. M. and Pastan, I. (1993). Biochemistry of multidrug resistance mediated by the mutlidrug transporter, Annu Rev Biochem, 62, 385–427.
   PubMed Web of Science ®Google Scholar
• Chaudhary, P. M., Mechetner, E. B. and Roninson, I. B. (1992). Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes, Blood, 80, 2735–2739.
   PubMed Web of Science ®Google Scholar
• Goldstein, L. J., Galski, H., Fojo, A., Willingham, M., Lai, S.-L., Gazdar, A., Pirker, R., Green, A., Crist, W., Brodeur, G. M., Lieber, M., Cossman, J., Gottesman, M. M. and Pastan, I. (1989). Expression of a multidrug resistance gene in human cancers, J Natl Cancer Inst, 81, 116–124.
   PubMed Web of Science ®Google Scholar
• Cole, S. P. C. and Deeley, R. G. (1998). Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP, BioEssays, 20, 931–940.
   PubMed Web of Science ®Google Scholar
• Slovak, M. L., Ho, J. P., Cole, S. P. C., Deeley, R. G., Greenberger, L., de Vries, E. G. E., Broxterman, H. J., Scheffer, G. L. and Scheper, R. J. (1995). The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: Evidence that chromosome breakage plays a key role in MRP or LRP gene amplification, Cancer Res, 55, 4214–4219.
   PubMed Web of Science ®Google Scholar
• Kuss, B. J., Geeley, R. G., Cole, S. P. C., Willman, C. L., Kopecky, K. J., Wolman, S. R., Eyre, H. J., Lane, S. A., Nancarrow, J. K., Whitmore, S. A. and Callen, D. F. (1994). Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16, prognostic implications, Lancet, 343, 1531–1534.
   PubMed Web of Science ®Google Scholar
• Grant, C. E., Valdimarsson, G., Hipfner, D. R., Almquist, K. C., Cole, S. P. C. and Deeley, R. G. (1994). Over-expression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs, Cancer Res, 54, 357–361.
   PubMed Web of Science ®Google Scholar
• D'Hondt, V., Caruso, M. and Bank, A. (1997). Retrovirus-mediated gene transfer of the multidrug resistance-associated protein (MRP) cDNA protects cells from chemotherapeutic agents, Human Gene Therapy, 8, 1745–1751.
   PubMed Web of Science ®Google Scholar
• Lorico, A., Rappa, G., Flavell, R. A. and Sartorelli, A. C. (1996). Double knockout of the MRP gene leads to increased drug sensitivity in vitro, Cancer Res, 56, 5351–5355.
   PubMed Web of Science ®Google Scholar
• Kruh, G. D., Gaughan, K. T., Godwin, A. and Chan, A. (1995). Expression pattern of MRP in human tissues and adult solid tumor cell lines, J Natl Cancer Inst, 87, 1256–1258.
   PubMed Web of Science ®Google Scholar
• Flens, M. J., Zaman, G. J. R., van der Valk, P., Izquierdo, M. A., Schroeijers, A. B., Scheffer, G. L., van der Groep, P., de Haas, M., Meijer, C. J. L. M. and Scheper, R. J. (1996). Tissue distribution of the multidrug resistance protein, Am J Path, 148, 1237–1247.
   PubMed Web of Science ®Google Scholar
• Breuninger, L. M., Paul, S., Gaughan, K., Miki, T., Chan, A., Aaronson, S. A. and Kruh, G. D. (1995). Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular distribution, Cancer Res, 55, 5342–5347.
   PubMed Web of Science ®Google Scholar
• Gaj, C. L., Anyanwutaku, I., Chang, Y. H. and Cheng, Y.- C. (1998). Decreased drug accumulation without increased drug efflux in a novel MRP-overexpressing multidrug-resistant cell line, Biochemical Pharmacology, 55, 1199–1211.
   PubMed Web of Science ®Google Scholar
• Müller, M., Meijer, C., Zaman, C. M. G., Borst, P., Scheper, R. J., Mulder, N. H., de Vries, E. G. E. and Jansen, P. L. M. (1994). Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport, Proc Natl Acad Sci USA, 91, 13033–13037.
   PubMed Web of Science ®Google Scholar
• Zaman, G. J. R., Lankelma, J., van Tellingen, O., Beijnen, J., Dekker, H., Paulusma, C., Oude Elferink, R. P. J., Baas, F. and Borst, P. (1995). Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein, Proc Natl Acad Sci USA, 92, 7690–7694.
   PubMed Web of Science ®Google Scholar
• Leier, I., Jedlitschky, G., Buchholz, U., Cole, S. P. C., Deeley, R. G. and Keppler, D. (1994). The MRP gene encodes an ATP dependent export pump for leukotriene C4 and structurally related conjugates, J Biol Chem, 269, 27807–27810.
   PubMed Web of Science ®Google Scholar
• Kavallaris, M. (1997). The role of multidrug resistance-associated protein (MRP) expression in multidrug resistance, Anti-Cancer Drugs, 9 17–25.
   Web of Science ®Google Scholar
• Fujii, R., Mutoh, M., Sumiwaza, T., Chen, Z.-S., Yoshimura, A. and Akiyama, A.-I. (1994). Adenosine triphosphate-dependent transport of leukotriene C4 by membrane vesicles prepared from cisplatin-resistant human epidermoid carcinoma tumor cells, J Natl Cancer Inst, 86, 1781–1784.
   PubMedGoogle Scholar
• Ishikawa, T., Akimaru, K., Kuo, M. T., Priebe, W. and Suzuki, M. (1995). How does the MRP/GS-X pump export doxorubicin? (letter), J Natl Cane Inst, 87, 1639–1640.
   PubMedGoogle Scholar
• Feller, N., Broxterman, H. J., Wahrer, D. C. and Pinedo, H. M. (1995). ATP dependent efflux of calcein by the multidrug resistance protein (MRP): No inhibition by intracellular glutathione depletion, FEBS Lett, 368, 385–388.
   PubMed Web of Science ®Google Scholar
• Tew, K. D. (1994). Glutathione-associated enzymes in anticancer drug resistance, Cancer Res, 54, 4313–4320.
   PubMed Web of Science ®Google Scholar
• Ishikawa, T., Bao, J.-J., Yamane, Y., Akimaru, K., Frindrich, K., Wright, C. D. and Kuo, M. T. (1996). Coordinated induction of MRP/GS-X pump and γ - glutamylcysteine synthetase by heavy metals in human leukemia cells, J Biol Chem, 271, 14981–14988.
   PubMed Web of Science ®Google Scholar
• Schroeijers, A. B., Siva, A. C., Scheffer, G. L., de Jong, M. C., Bolick, S. C. E., Dukers, D. F., Slootstra, J. W., Meloen, R. H., Wiemer, E., Kickhoefer, V. A., Rome, L. H. and Scheper, R. J. (2000). The Mr 193,000 vault protein is up-regulated in multidrug-resistant cancer cell lines, Cancer Res, 60, 1104–1110.
   PubMed Web of Science ®Google Scholar
• Scheffer, G. L., Wijngaard, P. L. J., Flens, M. J., Izquierdo, M. A., Slovak, M. L., Pinedo, H. M., Meijer, C. J. L. M., Clevers, H. C. and Scheper, R. J. (1995). The drug resistance-related protein LRP is the human major vault protein, Nature Medicine, 1, 578–582.
   PubMed Web of Science ®Google Scholar
• Kedersha, N. L. and Rome, L. H. (1986). Isolation and characterization of a novel ribonucleoprotein particle: large structures contain a single species of small RNA, J Cell Biol, 103, 699–709.
   PubMed Web of Science ®Google Scholar
• Scheper, R. J., Broxterman, H. J., Scheffer, G. L., Kaaijk, P., Dalton, W. S., van Heijningen, T. H. M., van Kalken, C. K., Slovak, M. L., de Vries, E. G. E., van de Valk, P., Meijer, C. J. L. M. and Pinedo, H. N. (1993). Overexpression of a Mr 110,000 vesicular protein innon-P-glycoprotein-mediated multidrug resistance, Cancer Res, 53, 1475–1479.
   PubMed Web of Science ®Google Scholar
• Wyler, B., Shao, Y., Schneider, E., Cianfriglia, M., Scheper, R. J., Frey, B. M., Gieseler, F., Schmid, L., Twentyman, P. R. and Lehnert, M. (1997). Intermittent exposure to doxorubicin in vitro selects for multifactorial non-P-glycoprotein-associated multidrug resistance in RPMI 8226 human myeloma cells, Br J Haematol, 97, 65–75.
   PubMed Web of Science ®Google Scholar
• Chugani, D. C., Rome, L. H. and Kedersha, N. L. (1993). Evidence that the vault ribonucleoprotein particles localize to the nuclear pore complex, J Cell Sci, 106, 23–29.
   PubMed Web of Science ®Google Scholar
• Rome, L. H., Kedersha, N. L. and Chugani, D. C. (1991). Unlocking vaults: organelles in search of a function, Trends Cell Biol, 1, 47–50.
   PubMedGoogle Scholar
• Izquierdo, M. A., Scheffer, G. L., Flens, M. J., Giaccone, G., Broxterman, H. J., Meijer, C. J. L. M., van der Valk, P. and Scheper, R. J. (1996). Broad distribution of the multidrug resistance-related vault protein in normal human tissues and tumors, Am J Pathol, 148, 877–887.
   PubMed Web of Science ®Google Scholar
• Kickhoefer, V. A., Rajavel, K. S., Scheffer, G. L., Dalton, W. S. Scheper, R. J. and Rome, L. H. (1998). Vaults are up-regulated in multidrug-resistant cancer cell lines, J Biol Chem, 273, 8971–8974.
   PubMed Web of Science ®Google Scholar
• Laurençot, C. M., Scheffer, G. L., Scheper, R. J. and Shoemaker, R. H. (1997). Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines, Int J Cancer, 72, 1021–1026.
   PubMed Web of Science ®Google Scholar
• Marie, J.- P., Legrand, O., Perrot, J.- Y., Chevillard, S., Huet, S. and Robert, J. (1997). Measuring multidrug resistance expression in human malignancies: Elaboration of consensus recommendations, Sem Hematol, 34(Suppl 5), 63–71.
   PubMedGoogle Scholar
• The site at address <http://www.med.rug.nl/mdl/humanabc.htm> is maintained by Dr. M. Müller. The human gene nomenclature site can be found at <http://www.gene.ucl.ac.uk/nomenclature/genefamily.shtml>.
   Google Scholar
• Longhurst, T. J., O'Neill, G. M., Harvie, R. M. and Davey, R. A. (1996). The anthracycline resistance-associated (ara) gene, a novel gene associated with multidrug resistance in a human leukaemia cell line, Br J Cancer, 74, 1331–1335.
   PubMed Web of Science ®Google Scholar
• O'Neill, G. M., Peters, G. B., Harvie, R. M., MacKenzie, H. B., Henness, S. and Davey, R. A. (1998). Amplification and expression of the ABC transporters ARA and MRP in a series of multidrug resistant leukaemia cell sublines, Br J Cancer, 77, 2076–2080.
   PubMed Web of Science ®Google Scholar
• Klugbauer, N. and Hofmann, F. (1996). Primary structure of a novel ABC transporter with a chromosomal localization on the band encoding the multidrug resistance-associated protein, FEBS Lett, 391, 61–65.
   PubMed Web of Science ®Google Scholar
• List, A. (2000). Developmental therapeutics for Drug Resistance Phenotypes. ASCO Educational book, Spring, 122–127.
   Google Scholar
• Scheffer, G. L., Maliepaard, M., Pijnenborg, A. C. L. M., van Gastelen, M. A., de Jong, M. C., Schroeijers, A. B., van der Kolk, D. M., Allen, J. D., Ross, D. D., van der Valk, P., Dalton, W. S., Schellens, J. H. M. and Scheper, R. J. (2000). Breast cancer resistance proteinis localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines, Cancer Res, 60, 2589–2593.
   PubMed Web of Science ®Google Scholar
• Izquierdo, M. A., Neefjes, J. J., Mathari, A. E. L., Flens, M. J., Scheffer, G. L. and Scheper, R. J. (1996). Overexpression of the ABC transporter TAP in multidrug-resistant human cancer cell lines, Br J Cancer, 74, 1961–1967.
   PubMed Web of Science ®Google Scholar
• Kool, M., Haas, M., Scheffer, G. L., Scheper, R. J., van Eijk, M. J. T., Juijn, J. A., Baas, F. and Borst, P. (1997). Analysis of expression of the cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), human cancer cell lines, Cancer Res, 57, 3537–3547.
   PubMed Web of Science ®Google Scholar
• Hoki, Y., Fujimor, A. and Pommier, Y. (1997). Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines, Cancer Chemother Pharmacol, 40, 433–438.
   PubMed Web of Science ®Google Scholar
• Feller, N., Kuiper, C. M., Lankelma, J., Ruhdal, J. K., Scheper, R. J., Pinedo, H. M. and Broxterman, H. J. (1995). Functional detection of MDR1/P170 and MRP1/P190-mediated resistance in tumour cells by flow cytometry, Br J Cancer, 72, 543–549.
   PubMed Web of Science ®Google Scholar
• Fisher, G. A., Lum, B. L., Hausdorff, J. and Sikic, B. I. (1996). Pharmacological considerations in the modulation of multidrug resistance, Br J Cancer, 32A, 1082–1088.
   Web of Science ®Google Scholar
• Barrand, M. A., Bagrij, T. and Neo, S.-Y. (1997). Multidrug resistance-associated protein: A protein distinct from P-glycoprotein involved in cytotoxic drug expulsion, Gen Pharmac, 28, 639–645.
   PubMedGoogle Scholar
• Filipits, M., Suchomel, R. W., Zöchbauer, S., Malayeri, R. and Pirker, R. (1996). Clinical relevance of drug resistance genes in malignant diseases, Leukemia, 10(Suppl 3), S10–S17.
   PubMedGoogle Scholar
• Tidefelt, U., Liliemark, J., Gruber, A., Liliemark, E., Sundman-Engberg, B., Juliusson, G., Stenke, L., Elmhorn-Rosenborg, A., Möllgård, L., Lehman, S., Xu, D., Covelli, A., Gustavsson, B. and Paul, C. (2000). P-glyco-protein inhibitor valdospar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia, J Clin One, 18, 1837–1844.
   PubMed Web of Science ®Google Scholar
• Leith, C. P., Kopecky, K. J., Godwin, J., McConnell, T., Slovak, M. L., Chen, I.-M., Head, D. R., Appelbaum, F. R. and Willman, C. L. (1997). Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study, Blood, 89, 3323–3329.
   PubMed Web of Science ®Google Scholar
• Wallner, J., Gisslinger, H., Gisslinger, B., Gsur, A., Göltz, M., Zöchbauer, S. and Pirker, R. (1994). MDR1 gene expression in chronic lymphocytic leukemia, Leuk Lymphoma, 13, 333–338.
   PubMed Web of Science ®Google Scholar
• Broxterman, H. J., Sonneveld, P., Pieters, R., Lankelma, J., Eekman, C. A., Loonen, A. H., Schoester, M., Ossenkoppele, G. J., Löwenberg, B., Pinedo, H. M. and Schuurhuis, G. J. (1999). Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in AML? Leukemia, 13, 258–265.
   PubMed Web of Science ®Google Scholar
• Marie, J.-P., Huet, S., Faussat, A.-M., Perrot, J.-Y., Chevillard, S., Barbu, V., Bayle, C., Boutonnat, J., Calvo, F., Campos-Guyotat, L., Colosetti, P., Cazin, J.-L., de Cremoux, P., Delvincourt, C., Demur, C., Drenou, B., Fenneteau, O., Feuillard, J., Garnier-Suillerot, A., Genne, P., Gorisse, M.-C., Gosselin, P., Jouault, H., Lacave, R., Le Calvez, G., Leglise, M.-C., Leonce, S., Manfait, M., Maynadie, M., Merle-Beral, H., Merlin, J.-L., Mousseau, M., Morjani, H., Picard, F., Pinguet, F., Poncelet, P., Racadot, E., Raphael, M., Richard, B., Rossi, J.-F., Schlegel, N., Vielh, P., Zhou, D.-C. and Robert, J. (1997). Multicentric evaluation of the MDR phenotype in leukemia. French Network of the Drug Resistance Intergroup, and Drug Resistance Network of Assistance Publique-Hôpitaux de Paris, Leukemia, 11, 1086–1094.
   PubMed Web of Science ®Google Scholar
• Leith, C. P., Kopecky, K. J., Chen, I.-M., Eijdems, L., Slovak, M. L., McConnel, T. S., Head, D. R., Weick, J., Grever, M. R., Appelbaum, F. R. and Willman, C. L. (1999). Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia. A Southwest Oncology Group Study, Blood, 94, 1086–1099.
   PubMed Web of Science ®Google Scholar
• Samdani, A., Vijapurkar, U., Grimm, M. A., Spier, C. S., Grogan, T. M., Glinsmann-Gibson, B. J. and List, A. F. (1996). Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML), Leukemia Res, 20, 175–180.
   PubMed Web of Science ®Google Scholar
• van den Heuvel-Eibrink, M. M., van der Holt, B., te Boekhorst, P. A. W., Pieters, R., Schoester, M., Löwenberg, B. and Sonneveld, P. (1997). MDR1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia, Br J Haematol, 99, 76–83.
   PubMed Web of Science ®Google Scholar
• Willman, C. (1997). The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: Studies of the Southwest Oncology Group Leukemia Research Program, Sem Hematol, 34(Suppl 5), 25–33.
   PubMed Web of Science ®Google Scholar
• Schaich, M., Illmer, T., Harbich, E. Soucek, S., Koch, R., Neubauer, A. and Ehninger, G., for the AML SHG 96 study group (1999). MRP resistance gene expression as independent prognostic factor in adult AML patients in adult AML patients ⩽ 60 years with intermediate group cytogenetics (abstract). Blood, 94 (Suppl 1, part 1), 69a.
   Google Scholar
• List, A. F., Spier, C. S., Grogan, T. M., Johnson, C., Roe, D. J., Greer, J. P., Wolff, S. N., Broxterman, H. J., Scheffer, G. L., Scheper, R. J. and Dalton, W. S. (1996). Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia, Blood, 87, 2464–2469.
   PubMed Web of Science ®Google Scholar
• Borg, A. G., Burgess, R., Green, L. M., Scheper, R. J. and Liu Yin, J. A. (1998). Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict poor response to chemotherapy and reduced patient survival, Br J Haematol, 103, 1083–1091.
   PubMed Web of Science ®Google Scholar
• Hart, S. M., Ganeshaguru, K., Scheper, R. J., Prentice, H. G., Hoffbrand, A. V. and Mehta, A. B. (1997). Expression of the human major vault protein LRP in acute myeloid eukemia, Exp Hematology, 25, 1227–1232.
   PubMed Web of Science ®Google Scholar
• Cornelissen, J. J., Sonneveld, P., Schoester, M., Raaijmakers, H. G. P., Nieuwenhuis, H. K., Dekker, A. W. and Lokhorst, H. M. (1994). MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents, J Clin One, 12, 115–119.
   PubMed Web of Science ®Google Scholar
• Sonneveld, P., Lokhorst, H. M. and Vossebeld, P. (1997). Drug resistance in multiple myeloma, Sem Hematol, 34 (Suppl 5), 34–39.
   PubMed Web of Science ®Google Scholar
• Grogan, T. M., Spier, C. M., Salmon, S. E., Matzner, M., Rybski, J., Weinstein, R. S., Scheper, R. J. and Dalton, W. S. (1993). P-glycoprotein expression in human plasma cell myeloma: Correlation with prior chemotherapy, Blood, 81, 490–495.
   PubMed Web of Science ®Google Scholar
• Raaijmakers, H. G. P., Izquierdo, M. A. I., Lokhorst, H. M., de Leeuw, C., Belien, J. A. M., Bloem, A. C., Dekker, A. W., Scheper, R. J. and Sonneveld, P. (1998). Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma, Blood, 91, 1029–1036.
   PubMed Web of Science ®Google Scholar
• Lepelley, P., Poulain, S., Grardel, N., Preudhomme, C., Cosson, A. and Fenaux, P. (1998). Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes, Leuk Lymphoma, 29, 547–551.
   PubMed Web of Science ®Google Scholar
• Futshcer, B. W., Foley, N. E., Gleason-Guzman, M. C., Meltzer, P. S., Sullivan, D. M. and Dalton, W. S. (1996). Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance, Int J Cancer, 66, 520–525.
   PubMed Web of Science ®Google Scholar
• Durie, B. G. M. and Dalton, W. S. (1988). Reversal of drug resistance in multiple myeloma with verapamil, Br J Hematol, 68, 203–206.
   PubMed Web of Science ®Google Scholar
• Dalton, W. S., Grogan, T. M., Meltzer, P. S., Scheper, R. J., Durie, B. G. M., Taylor, C. W., Miller, T. P. and Salmon, S. E. (1989). Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy, J Clin Oncol, 7, 415–424.
   PubMed Web of Science ®Google Scholar
• Miller, T. P., Grogan, T. M., Dalton, W. S., Spier, C. M., Scheper, R. J. and Salmon, S. E. (1991). P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high dose verapamil, J Clin One, 9, 17–24.
   PubMed Web of Science ®Google Scholar
• Wilson, W. H., Bates, S. E., Fojo, A., Bryant, G., Zhan, Z., Regis, J., Wittes, R. E., Jaffe, E. S., Steinberg, S. M., Herdt, J. and Chabner, B. A. (1995). Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy, J Clin One, 13, 1995–2004.
   PubMed Web of Science ®Google Scholar
• Dalton, W. S., Crowley, J. J., Salmon, S. S., Grogan, T. M., Laufman, L. R., Weiss, G. R. and Bonnett, J. D. (1994). A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study, Cancer, 75, 815–820.
   Web of Science ®Google Scholar
• Sonneveld, P. Durie, B. G. M., Lokhorst, H. M., Marie, J.-P., Solbu, G., Suciu, S., Zittoun, R., Lowenberg, B. and Nooter, K. G. (1992). Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON, Lancet, 340, 255–259.
   PubMed Web of Science ®Google Scholar
• Marie, J.-P., Bastie, N.-N., Coloma, F., Suberville, A.-M. F., Delmer, A., Rio, B., Delmas-Marsalet, B., Leroux, G., Casassus, P., Eaumelou, E., Catalin, J. and Zittoun, R. (1993). Cyclosporin A as a modifier agent in salvage treatment of acute leukemia (AL), Leukemia, 7, 821–824.
   PubMed Web of Science ®Google Scholar
• List, A. F., Spier, C., Greer, J., Wolff, S., Hutter, J., Dorr, R., Salmon, S., Futscher, B., Baier, M. and Dalton, W. S. (1993). Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia, J Clin Oncol, 11, 1652–1660.
   PubMed Web of Science ®Google Scholar
• List, A. F., Kopecky, K. J., Slovak, M. L., Willman, C. L., Head, D. R. and Appelbaum, F. R. (1999). A randomized phase III study of cyclosporine (CsA) modulation of anthracycline resistance in CML-blast phase: Southwest Oncology Group (SWOG) study 9032 (abstract), Blood, 94(Suppl 1, part 2), 276b.
   Google Scholar
• List, A. F., Kopecky, K. J., Willman, C. L., Spier, C., Dorr, R., Flaherty, L., Appelbaum, F. and Hynes, H. (1998). Benefit of cyclosporine (CsA) modulation of anthracycline resistance in high-risk AML: A Southwest Oncology Group (SWOG) study (abstract), Blood, 92 (Suppl 1, part 1), 312a.
   Google Scholar
• Lee, E. J., George, S. L., Caligiuri, M., Szatrowski, T. P., Powell, B. L., Lemke, S., Dodge, R. K., Smith, R., Baer, M. and Schiffer, C. A. (1999). Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420, J Clin Oncol, 17, 2831–2839.
   PubMed Web of Science ®Google Scholar
• Baer, M. R., George, S. L., Dodge, R. K., Cooke, K., Caligiuri, M. A., Powell, B. L., Kolitz, J. E., Schiffer, C. A. and Larson, R. A. (1999). Phase III study of PSC-833 modulation of multidrug resistance (MDR) in previously untreated acute myeloid leukemia (AML) patients ⩾ 60 years (CALGB 9720) (abstract), Blood, 94 (Suppl 1, part 1), 383a.
   Google Scholar
• Advani, R., Saba, H. I., Tallman, M. S., Rowe, J. M., Wiernik, P. H., Ramek, J., Dugan, K., Lum, B., Villena, J., Davis, E., Paietta, E., Litchman, M., Sikic, B. I. and Greenberg, P. L. (1999). Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valdospar), Blood, 93, 787–795.
   PubMed Web of Science ®Google Scholar
• Greenberg, P., Advani, R., Tallman, M., Letendre, L., Saba, H., Dugan, K., Lee, S. J., Lum, B., Sikic, B. I., Paietta, E., Bennett, J. M. and Rowe, J. M. (1999). Treatment of refractory/relapsed AML with PSC833 plus mitoxantrone, etoposide, cytarabine (PSC-MEC) vs. MEC: Randomized phase III trial (E2995) (abstract), Blood, 94(Suppl 1, part 1), 383a.
   Google Scholar
• Solary, E., Caillot, D., Chauffert, B., Casasnovas, R.-O., Dumas, M., Maynadie, M. and Guy, H. (1992). Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute myeloid leukemia, J Clin One, 10, 1730–1736.
   PubMed Web of Science ®Google Scholar
• Wattel, E., Solary, E., Hecquet, B., Caillot, D., Ifrah, N., Brion, A., Mahe, B., Milpied, N., Janvier, M., Guerci, A., Rochant, H., Cordonnier, C., Dreyfus, F., Buzyn, A., Hoang-Ngoc, L., Stoppa, A. M., Gratecos, N., Sadoun, A., Stamatoulas, A., Tilly, H., Brice, P., Maloisel, F., Lioure, B., Desablens, B., Pignon, B., Abgrall, J. P., Leporrier, M., Dupriez, B., Guyotat, D., Lepelley, P. and Fenaux, P. (1998). Quinine improves the results of intensive chemotherapy in myelodysplastic syndromes expressing P-glycoprotein: Results of a randomized study, Br J Haematol, 102, 1015–1024.
   PubMed Web of Science ®Google Scholar
• Rowinsky, E. K., Smith, L., Wang, Y.-M., Chaturvedi, P., Villalona, M., Campbell, E., Aylesworth, C., Eckhardt, S. G., Hammond, L., Kraynak, M., Drengler, R., Sephenson, Jr, J., Harding, M. W., Von Hoff, D. D. (1998). Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP, J Clin One, 16, 2964–2976.
   PubMed Web of Science ®Google Scholar